Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -41.56% is in line with its 5-year average of -44.69%, near the high end of its 5-year range (-104.80%–-23.14%).
As of the fiscal period ended Tuesday, June 30, 2026. 40.62% above its 12-month average of -69.99%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -41.56%.
RETURN ON EQUITY (ROE)
-41.56%
RETURN ON EQUITY (ROE) AVG TTM
-69.99%
RETURN ON EQUITY (ROE) AVG 3Y
-56.16%
RETURN ON EQUITY (ROE) AVG 5Y
-44.69%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+40.62%
CURRENT VS 3Y AVG
+26.01%
CURRENT VS 5Y AVG
+7.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.53%
median of 496 covered companies
CURRENT VS SECTOR MEDIAN
-7.85%
vs the sector median at left
Aura Biosciences, Inc.
Market Cap
$638.20M
Return on Equity (ROE)
-41.56%
TTM Avg
-69.99%
3Y Avg
-56.16%
5Y Avg
-44.69%
Market Cap
$649.13M
Return on Equity (ROE)
-43.95%
TTM Avg
-29.61%
3Y Avg
-34.61%
5Y Avg
-30.48%
Market Cap
$625.03M
Return on Equity (ROE)
-24.06%
TTM Avg
-36.09%
3Y Avg
-34.99%
5Y Avg
-44.03%
Market Cap
$621.12M
Return on Equity (ROE)
-8.42%
TTM Avg
-4.61%
3Y Avg
-3.17%
5Y Avg
11.46%
Market Cap
$620.40M
Return on Equity (ROE)
-21.51%
TTM Avg
-20.05%
3Y Avg
-35.91%
5Y Avg
-26.18%
Market Cap
$658.52M
Return on Equity (ROE)
-75.79%
TTM Avg
-55.51%
3Y Avg
-59.06%
5Y Avg
-60.41%
Market Cap
$665.25M
Return on Equity (ROE)
-108.93%
TTM Avg
-72.41%
3Y Avg
-64.95%
5Y Avg
-55.74%
Market Cap
$666.85M
Return on Equity (ROE)
2.89%
TTM Avg
20.45%
3Y Avg
11.91%
5Y Avg
-3.26%
Market Cap
$598.37M
Return on Equity (ROE)
N/A
TTM Avg
-4.73%
3Y Avg
76.70%
5Y Avg
93.92%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $638.20M | -41.56% | -69.99% | -56.16% | -44.69% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $649.13M | -43.95% | -29.61% | -34.61% | -30.48% |
| Climb Bio, Inc. (CLYM)vs › | $625.03M | -24.06% | -36.09% | -34.99% | -44.03% |
| Fulgent Genetics, Inc. (FLGT)vs › | $621.12M | -8.42% | -4.61% | -3.17% | 11.46% |
| AngioDynamics, Inc. (ANGO)vs › | $620.40M | -21.51% | -20.05% | -35.91% | -26.18% |
| Helus Pharma Inc. (HELP)vs › | $658.52M | -75.79% | -55.51% | -59.06% | -60.41% |
| Annexon, Inc. (ANNX)vs › | $665.25M | -108.93% | -72.41% | -64.95% | -55.74% |
| MiMedx Group, Inc. (MDXG)vs › | $666.85M | 2.89% | 20.45% | 11.91% | -3.26% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | N/A | -4.73% | 76.70% | 93.92% |
| Faeth Therapeutics, Inc. (FTH)vs › | $683.14M | -113.05% | -95.98% | -72.88% | -73.85% |
ROE
-41.6%
ROA
-37.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -41.56% |
| 2026-03-31 | -104.80% |
| 2025-12-31 | -77.56% |
| 2025-09-30 | -67.96% |
| 2025-06-30 | -58.05% |
| 2025-03-31 | -74.00% |
| 2024-12-31 | -57.19% |
| 2024-09-30 | -47.64% |
| 2024-06-30 | -42.14% |
| 2024-03-31 | -37.67% |
| 2023-12-31 | -33.83% |
| 2023-09-30 | -46.69% |
| 2023-06-30 | -40.99% |
| 2023-03-31 | -35.17% |
| 2022-12-31 | -30.05% |
| 2022-09-30 | -46.79% |
| 2022-06-30 | -36.23% |
| 2022-03-31 | -29.88% |
| 2021-12-31 | -23.14% |
| 2021-09-30 | -42.13% |
| 2021-06-30 | -25.19% |
| 2021-03-31 | -22.30% |
| 2020-12-31 | -134.59% |
